Viking Global Investors

Neurona Therapeutics is a biotechnology company developing cell-based therapies for treating neurological disorders. Founded by neuroscientists at UCSF in 2008, the company focuses on generating therapeutic compositions of specific nerve cells for targeted delivery into the injured nervous system.

Neurona Therapeutics is a biotechnology company developing cell-based therapies for treating neurological disorders. Founded by neuroscientists at UCSF in 2008, the company focuses on generating therapeutic compositions of specific nerve cells for targeted delivery into the injured nervous system.

Mantra Bio, Inc. is a biotechnology company focused on developing targeted therapeutics through its proprietary platform for engineering Targeted Exosome Vehicles (TEVs). Founded in 2016 and based in San Francisco, California, the company utilizes its REVEAL platform, which integrates computational biology, wet lab techniques, and automation. This innovative approach leverages the diversity of exosomes to design and optimize therapeutics aimed at various tissue and cellular targets. Mantra Bio has also established a scalable biomanufacturing process to ensure the reproducibility and high purity of its next-generation therapeutics, enabling medical practitioners to address challenging diseases effectively.

Talkdesk Inc., founded in 2011 by Cristina Fonseca and Tiago Paiva, specializes in browser-based cloud contact center software for small businesses. Headquartered in San Francisco with offices across Europe and North America, Talkdesk offers an end-to-end solution that optimizes customer engagement, workforce management, and analytics. Its platform enables users to identify callers before answering, provides comprehensive customer insights from various sources, monitors call performance in real-time, and offers intelligent customer self-service data for agents. With over 1,400 enterprise clients worldwide, including IBM and Acxiom, Talkdesk helps businesses enhance customer satisfaction, productivity, and cost savings through its adaptable platform.

Iterable is an AI-powered customer communication platform for mid-market and enterprise B2C brands, enabling cross-channel messaging across email, mobile, social and the web. The platform uses behavioral data and proprietary algorithms to determine optimal timing for engagement, supports real-time segmentation, automation, personalization and A/B testing, and facilitates lifecycle campaigns that activate customers at scale. It targets e-commerce, media, financial services and political campaigns, providing growth marketing solutions such as shopping cart abandonment and transactional messaging. By harmonizing communications and focusing on timely, contextually relevant interactions, Iterable helps organizations drive personalized customer experiences while avoiding channel fatigue.

Mantra Bio, Inc. is a biotechnology company focused on developing targeted therapeutics through its proprietary platform for engineering Targeted Exosome Vehicles (TEVs). Founded in 2016 and based in San Francisco, California, the company utilizes its REVEAL platform, which integrates computational biology, wet lab techniques, and automation. This innovative approach leverages the diversity of exosomes to design and optimize therapeutics aimed at various tissue and cellular targets. Mantra Bio has also established a scalable biomanufacturing process to ensure the reproducibility and high purity of its next-generation therapeutics, enabling medical practitioners to address challenging diseases effectively.

Talkdesk Inc., founded in 2011 by Cristina Fonseca and Tiago Paiva, specializes in browser-based cloud contact center software for small businesses. Headquartered in San Francisco with offices across Europe and North America, Talkdesk offers an end-to-end solution that optimizes customer engagement, workforce management, and analytics. Its platform enables users to identify callers before answering, provides comprehensive customer insights from various sources, monitors call performance in real-time, and offers intelligent customer self-service data for agents. With over 1,400 enterprise clients worldwide, including IBM and Acxiom, Talkdesk helps businesses enhance customer satisfaction, productivity, and cost savings through its adaptable platform.

Checkerspot, Inc. is a biotechnology company based in Berkeley, California, founded in 2016. It specializes in the development of sustainable performance materials derived from microalgae and biobased oils. The company focuses on innovating materials at a molecular level, utilizing its expertise in molecular foundry, chemistry, material science, and fabrication technology. Checkerspot aims to expand the range of molecular building blocks available for high-performance materials, particularly in industrial applications such as polyurethanes and textile finishes. Through its pioneering approach, Checkerspot contributes to the advancement of sustainable materials in various industries.

Iterable is an AI-powered customer communication platform for mid-market and enterprise B2C brands, enabling cross-channel messaging across email, mobile, social and the web. The platform uses behavioral data and proprietary algorithms to determine optimal timing for engagement, supports real-time segmentation, automation, personalization and A/B testing, and facilitates lifecycle campaigns that activate customers at scale. It targets e-commerce, media, financial services and political campaigns, providing growth marketing solutions such as shopping cart abandonment and transactional messaging. By harmonizing communications and focusing on timely, contextually relevant interactions, Iterable helps organizations drive personalized customer experiences while avoiding channel fatigue.

Checkerspot, Inc. is a biotechnology company based in Berkeley, California, founded in 2016. It specializes in the development of sustainable performance materials derived from microalgae and biobased oils. The company focuses on innovating materials at a molecular level, utilizing its expertise in molecular foundry, chemistry, material science, and fabrication technology. Checkerspot aims to expand the range of molecular building blocks available for high-performance materials, particularly in industrial applications such as polyurethanes and textile finishes. Through its pioneering approach, Checkerspot contributes to the advancement of sustainable materials in various industries.

Talkdesk Inc., founded in 2011 by Cristina Fonseca and Tiago Paiva, specializes in browser-based cloud contact center software for small businesses. Headquartered in San Francisco with offices across Europe and North America, Talkdesk offers an end-to-end solution that optimizes customer engagement, workforce management, and analytics. Its platform enables users to identify callers before answering, provides comprehensive customer insights from various sources, monitors call performance in real-time, and offers intelligent customer self-service data for agents. With over 1,400 enterprise clients worldwide, including IBM and Acxiom, Talkdesk helps businesses enhance customer satisfaction, productivity, and cost savings through its adaptable platform.

Checkerspot, Inc. is a biotechnology company based in Berkeley, California, founded in 2016. It specializes in the development of sustainable performance materials derived from microalgae and biobased oils. The company focuses on innovating materials at a molecular level, utilizing its expertise in molecular foundry, chemistry, material science, and fabrication technology. Checkerspot aims to expand the range of molecular building blocks available for high-performance materials, particularly in industrial applications such as polyurethanes and textile finishes. Through its pioneering approach, Checkerspot contributes to the advancement of sustainable materials in various industries.

Eidos Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Francisco, California, specializing in the development of therapies for diseases associated with transthyretin (TTR) amyloidosis (ATTR). Founded in 2013, the company is advancing its lead candidate, AG10, which is currently undergoing phase 3 clinical trials. AG10 is an orally administered small molecule designed to stabilize tetrameric TTR, aiming to interrupt the pathological processes that lead to ATTR. As a subsidiary of BridgeBio Pharma, Eidos Therapeutics is committed to addressing the clinical needs related to TTR and amyloidosis through innovative, genetically targeted therapies.

EpiBiome, Inc. is a precision microbiome engineering company based in South San Francisco, California, founded in 2013. The company is dedicated to developing therapies that address infectious diseases in humans and agriculture without relying on small-molecule antibiotics. EpiBiome focuses on phage therapy, which targets specific strains within the microbiome, effectively treating antibiotic-resistant infections. Its applications include treatment for mastitis in dairy cows and addressing infections caused by Escherichia coli in humans. By utilizing advanced sequencing and bioinformatic processes, EpiBiome aims to identify pathogenic bacteria and microbiome changes that contribute to disease, offering innovative alternatives to combat the rising threat of antibiotic resistance. As of July 2018, it operates as a subsidiary of Locus Biosciences, Inc.

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients' lives by developing therapies that overcome resistance in cancer. Its lead product candidate, ORIC-101, targets the glucocorticoid receptor linked to resistance across various solid tumors. ORIC's second product candidate, ORIC-533, inhibits CD73 to address resistance to chemotherapy and immunotherapy. The company is also developing precision medicines targeting other cancer resistance mechanisms.